Next-Generation Japanese GLP-1 weight loss pills: Seeking North American Distributors
A carbonated granule supplement based on advanced Japanese immune research and a science-based approach to prevent over-eating enters the expanding U.S. weight loss market.
Japan, 12th Mar 2026 – Asa Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; CEO: Tomoko Iwase), a manufacturer and distributor of health foods, has launched North American expansion of a next-generation diet supplement utilizing proprietary carbonated granule technology, targeting the rapidly growing global “GLP-1 (appetite-suppressing hormone)” support market. In conjunction with this launch, the company has formally begun inviting applications from strategic partners (distributors), including clinics, fitness chains, and luxury spas.
In the United States, GLP-1 receptor agonists such as Mounjaro have attracted...
